Atlas Trials

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT03551275 · COMPLETED

Trial details

NCT number
NCT03551275
Sponsor
Biocad
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Multiple Sclerosis
Start date
2018-02-22
Primary completion
2018-10-18
Enrollment
24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.